Efficacy and Safety of Switching From Boosted Lopinavir to Boosted Atazanavir in Patients With Virological Suppression Receiving a LPV/r-Containing HAART: The ATAZIP Study.

The article presents a study which examines the efficacy and safety of switching from boosted lopinavir (LPV/r) to boosted atazanavir (ATV/r) in virologically suppressed HIV-infected patients receiving a LPV/r-containing highly active antiretroviral therapy (HAART). The randomized, open-label, noninferiority trial found balanced baseline characteristics. Moreover, the study also found that switching to ATV/r provided comparable efficacy and safety profile with improved lipid parameters.